| Name | Saxagliptin |
| Classes |
Antidiabetic Agent Metabolic Agent Dipeptidyl peptidase 4 Inhibitor |
| Diseases |
Type 2 Diabetes Mellitus Hormonal Disorder |
Bangla
EnglishSaxagliptin
Saxagliptin is an oral hypoglycemic medication. It belongs to a class of hypoglycemics called the Dipeptidyl Peptidase 4 inhibitors (DPP4). DPP4 is an enzyme that metabolizes Glucagon like peptide, which is an incretin. So, DPP4 inhibitors work by increasing the concentration of incretins in the blood which ultimately results in the increased secretion of insulin.
Saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Recommended dosage is 2.5 mg or 5 mg once daily taken regardless of meals.
- Patients with moderate or severe renal impairment, or end-stage renal disease (CrCl ≤ 50 mL/min): Recommended dosage is 2.5 mg once daily regardless of meals.
- Assess renal function before starting Saxagliptin and periodically thereafter.
- 2.5 mg daily is recommended for patients also taking strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole).
Side effects reported with use of saxagliptin are as follows-
- hypoglycemia
- upper respiratory tract infection
- nasopharyngitis
- headache
- Postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, have been received. If pancreatitis is suspected, stop taking Saxagliptin right away.
- There have been postmarketing reports of acute renal failure, requiring dialysis in some cases. Dosage reduction is advised in patients with moderate to severe renal insufficiency, as well as those with ESRD. Prior to starting Saxagliptin and on a regular basis, renal function should be evaluated.
- When Saxagliptin is combined with an insulin secretagogue (e.g., sulfonylurea) or insulin therapy, the risk of hypoglycemia increases. To reduce the risk of hypoglycemia, consider lowering the dose of the sulfonylurea or insulin.
- There have been postmarketing reports of serious allergic and hypersensitivity reactions in Saxagliptin patients, including anaphylaxis, angioedema, and exfoliative skin conditions such as Stevens-Johnson syndrome. In such cases, discontinue Saxagliptin immediately, assess for other potential causes, institute appropriate monitoring and treatment, and begin alternative diabetes treatment.
- There have been no clinical studies that show conclusive evidence of Saxagliptin or any other anti-diabetic drug lowering macrovascular risk.
Contraindication
Contraindicated in patients hypersensitive to Sitagliptin or similar drugs such as-
None known.
None known.